Format

Send to

Choose Destination
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec;23(6):1679-83. doi: 10.7534/j.issn.1009-2137.2015.06.028.

[Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion].

[Article in Chinese]

Author information

1
Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China.
2
Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China. E-mail: sunwanjun1974@sohu.com.

Abstract

OBJECTIVE:

To investigate the efficacy and safety of MA (mitoxantrone and cytarabine) regimen chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of acute myeloid leukemia (AML) patients aged over 80 years.

METHODS:

Four elderly patients with AML were treated in Chinese Second Artillery General Hospital from August 2008 to September 2013. The proportion of male to female was 1 : 3 and the median age 83 (80-85) years. All patients received programmed infusions of G-PBHSC after MA regimen chemotherapy without graft-versus-host disease (GVHD) prophylaxis. After complete remission (CR), patients only received G-PBHSC infusion without chemotherapy.

RESULTS:

Three cases achieved CR and their disease free survival (DFS) time was 18, 8, 6 months, respectively. 1 case did not reach remission after 2 cycles chemotherapy. The median overall survival (OS) time was 10 (3-20) months. No GVHD was observed in any of the patients during treatment. Concludsion: The combination of chemotherapy and programmed haploidentical G-PBHSC infusion is an alternative approach for AML patients aged over 80 years.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center